Hydroxycinnamic acid derivatives: a potential class of natural compounds for the management of lipid metabolism and obesity

Md Ashraful Alam, Nusrat Subhan, Hemayet Hossain, Murad Hossain, Hasan Mahmud Reza, Md Mahbubur Rahman and M Obayed Ullah

Abstract

Hydroxycinnamic acid derivatives are important class of polyphenolic compounds originated from the Mavolanate-Shikimate biosynthesis pathways in plants. Several simple phenolic compounds such as cinnamic acid, p-coumaric acid, ferulic acid, caffeic acid, chlorogenic acid, and rosmarinic acid belong to this class. These phenolic compounds possess potent antioxidant and anti-inflammatory properties. These compounds were also showed potential therapeutic benefit in experimental diabetes and hyperlipidemia. Recent evidences also suggest that they may serve as valuable molecule for the treatment of obesity related health complications. In adipose tissues, hydroxycinnamic acid derivatives inhibit macrophage infiltration and nuclear factor κB (NF-κB) activation in obese animals. Hydroxycinnamic acid derivatives also reduce the expression of the potent proinflammatory adipokines tumor necrosis factor-α (TNFα), monocyte chemoattractant protein-1 (MCP-1), and plasminogen activator inhibitor type-1 (PAI-1), and they increase the secretion of an anti-inflammatory agent adiponectin from adipocytes. Furthermore, hydroxycinnamic acid derivatives also prevent adipocyte differentiation and lower lipid profile in experimental animals. Through these diverse mechanisms hydroxycinnamic acid derivatives reduce obesity and curtail associated adverse health complications.

Keywords: Hydroxycinnamic acid, Obesity, Diabetes, Dyslipidemia, Inflammation

Background

Metabolic syndrome is a cluster of non-communicable diseases includes central obesity, diabetes, insulin resistance, hypertension and dyslipidemia. Prevalence of obesity and diabetes are increasing day by day among children, young and elderly populations both in developed and developing countries [1–3]. A sedentary nature of jobs and high calorie diet mainly western style diet are the main causes of developing obesity and diabetes, consequently metabolic syndrome [1, 4]. Ever increasing obese and diabetes population are causing serious problems for the management of health sector as well as increasing personal health risks [4]. Recent evidence also suggests that increased body fat mass causes cardiovascular diseases and increases morbidity and mortality in human [5, 6]. Dietary modification, for example decreasing the intake of high fat and high carbohydrate could be a possible way of reducing the risk of fat accumulation in the body. In addition, several dietary approaches such as Mediterranean diet or diet containing high amount of fibres, fruits and vegetables would be valuable for the prevention of hypertension, diabetes, dyslipidemia and obesity [7, 8]. Mediterranean diet or fruits and vegetables possess large amount of phenolic or polyphenolic compounds. It is now widely recognized that, phenolic or polyphenolic compounds are strong antioxidant substances and showed anti-inflammatory properties [9, 10]. Some of them are also...
effective against diabetes, insulin resistance and dyslipidemia [11–15]. Many of them also prevent hypertension and cardiovascular diseases [16]. All these biological activities are mainly regulated by phenolic acid’s ability to scavenge free radicals generated due to excess nutrient supply to the tissues in obesity, or they may regulate the energy homeostasis and inflammatory pathways. This work will thus review the potential health benefit of hydroxycinnamic acid derivatives in obesity and metabolic syndrome and their possible mechanism of action.

**Obesity and energy homeostasis, mechanism of fat metabolism**

Obesity can be defined as the accumulation of excess fat due to the increased energy intake and lack of energy expenditure. However, World Health Organization uses Body Mass Index (BMI) as a parameter for defining obesity. According to WHO, BMI >30 is considered as moderately obese and BMI > 35 is considered as severely obese in human [17]. Global obesity in young to adult population is increasing tremendously in recent years [18, 19]. Lack of physical movements, sedentary nature of work and consumption of diet containing high carbohydrate and high fat are responsible for the development of obesity [20]. Thus, increased energy expenditure would be a contributing factor to control and manage obesity and related pathophysiological conditions. Mitochondrial biogenesis are the major pathways in various cell types like, liver, adipose tissue, skeletal muscle etc. to increase ATP production and energy expenditure. Decreased mitochondrial function was observed in obesity and metabolic disorder [21–23]. In obese condition, abundance of fuel supply e.g., fatty acid and glucose overwhelm the mitochondrial electron transport chain and increased the superoxide production [24–27]. Mitochondrial biogeneses are regulated via several transcriptional regulatory factors like AMPK, PPAR-γ and PGC-1α [28, 29]. AMPK regulated PPAR-γ and PGC-1α activation stimulated most of the transcriptional signal to increase fatty acid oxidation and mitochondrial function [30–32].

**AMPK**

AMP-activated protein kinase (AMPK) is a cellular fuel gauge, maintaining intracellular energy balance in mammalian cells [33]. AMPK signalling pathway is activated by elevation of the AMP/ATP ratio due to the decreased ATP synthesis by mitochondria or by increased energy (ATP) expenditure [33]. Glucose deprivation, hypoxia or ischaemia, or metabolic poisons are few factors which may inhibit glycolysis, tricarboxylic acid cycle or oxidative phosphorylation and disturb energy balance by interfering with ATP synthesis, which may trigger activation of AMPK signalling [34]. AMPK activation is necessary for the transcriptional regulation of energy demand. Mice expressing a dominant-negative form of AMPK failed to increase mitochondrial biogenesis in response to energy deprivation in skeletal muscles [35]. In contrast, lipid oxidation and mitochondrial activity was increased in mice over expressing the phosphorylated AMPK [36, 37]. Several ligands such as thiazolidinediones (for example, rosiglitazone) and biguanides (metformin) both activates AMPK [38]. Thiazolidinediones and biguanides inhibits complex I of the mitochondrial respiratory chain and elevates cellular AMP/ATP ratios [39]. Furthermore, mice fed with AMPK agonists increased oxidative gene expression, enhanced endurance capacity and gave protection against metabolic disease [40, 41]. AMPK can also be activated by metabolic stresses such as muscle contraction or hypoxia, and modulated by hormones and cytokines affecting whole-body energy balance such as leptin, adiponectin, resistin, ghrelin and cannabinoids [33].

**PPAR-γ**

AMPK activation increased the fatty acid oxidation through activating the PPAR-γ and PGC-1α [42]. Peroxisome proliferator activator protein-γ (PPAR-γ) is highly expressed in adipose tissues [43]. The expression of PPARγ in liver is very low compared to the level present in adipose tissue [43–45]. The actions of PPAR-γ are mediated by two protein isoforms, PPARγ1 and PPARγ2 [46]. PPARγ1 is widely expressed while PPARγ2 is restricted to the adipose tissue only [46]. Fatty acids binding activates PPAR-γ [46]. Activation of PPARγ is necessary for adipocyte differentiation and fatty-acid storage [43, 44]. PPAR-γ deficient mice are devoid of adipose tissue and PPAR-γ+/− mice are characterized by a decreased adipose tissue mass [47, 48]. PPAR-γ is also important for anti-inflammatory pathways, lipid metabolism and regulates genes taking part in the release, transport and storage of fatty acids [49, 50]. Moreover, PPARγ is also responsible for the improvement of insulin resistance and plays an important role in glucose homeostasis. Mice lacking PPARγ in fat, muscle, or liver are predisposed to develop insulin resistance [51–54] while mice with increased PPARγ activities are protected from obesity-associated insulin resistance [55]. PPARγ is a ligand activated protein, thiazolidinediones are considered as the activator of PPARγ [56]. However, thiazolidinediones are adipogenic and responsible for moderate weight gain in patients taking thiazolidinediones [50, 57].

**PGC-1α**

Peroxisome proliferator activator protein-γ co-activator-1α (PGC-1α) is another regulator of lipid and glucose
metabolism. AMPK regulates PGC-1α at both gene and protein level [36]. PGC-1α directly co-activates multiple transcriptional factors such as the PPARs or the thyroid hormone receptor, glucocorticoid receptors and estrogen receptors [29, 58]. PGC-1α also increases mitochondrial biogenesis and respiration rates, as well as the uptake and utilization of substrates for energy production [59]. In brown adipose tissue (BAT), cold induces PGC-1α protein expression that controls adaptive thermogenesis [59]. Furthermore, fasting induces hepatic PGC-1α expression and increases gluconeogenesis, whereas in skeletal and cardiac muscle, exercise increases PGC-1α mediated mitochondrial biogenesis and respiration [60]. Phenolic compound resveratrol increased the PGC-1α activity and increased running time and consumption of oxygen in muscle fibers in mice [61]. Moreover, resveratrol increased insulin sensitivity, reduced insulin-like growth factor-1 (IGF-1) levels, increased AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor-gamma co-activator-1α (PGC-1α) activity, increased mitochondrial number, and improved motor function in middle-aged mice fed a high-calorie diet [62].

Inflammation and obesity

Inflammation is a protective response mechanism for tissue injury. Both acute and chronic inflammatory responses are responsible for the development of diabetes and insulin resistance [63, 64]. Recent research findings suggest that chronic low grade inflammation is developed in obese individuals and triggers adipocyte dysfunction [65]. Moreover, adipose tissues are playing a major role in secreting pro-inflammatory and inflammatory cytokines during obesity [66]. Pathologic growth of adipocyte houses many of inflammatory cytokines like TNF-alpha and IL-6 [67]. Inputs into this inflammatory response further stimulate ER stress, adipose tissue hypoxia, and adipocyte death [68–70]. Macrophage numbers in adipose tissues are also increased with obesity where they mainly scavenge the dead adipocytes [71, 72]. Macrophages are also responsible for the cytokine production in obese adipose tissues [73].

Hydroxycinnamic acid derivatives overview

Hydroxycinnamic acid derivatives (Fig. 1) comprise a large group of simple phenolic acids, found mainly in cereals, fruits and vegetables. A review has been published recently describing the occurrence, biosynthesis, and pharmacokinetics of hydroxycinnamic acid derivatives [74]. Ferulic acid, caffeic acid, p-coumaric acid, chlorogenic acid, sinapic acid, curcumin, and rosmarinic acid belongs to this important phenolic acid group. Hydroxycinnamic acids are abundant in fruits, vegetables and cereals and seeds of fruits [74]. In plant, hydroxycinnamic acid derivatives are synthesized by following the mavolinate and shikimate pathways where phenylalanine and tyrosine are two starter precursor molecules [74, 75]. Following several intermediate enzymatic process, shikimate pathways produced cinnamic acid, p-coumaric acid, caffeic acid, ferulic acid, sinapic acid to various complex lignin molecules [74, 75]. Hydroxycinnamic acid derivatives are also serving as precursor molecules for the stilbenes, chalcones, flavonoids, lignans, and anthocyanins [74].

![Fig. 1 Structures of hydroxyl cinnamic acid derivatives. Cinnamic acid, p-coumaric acid, ferulic acid, caffeic acid, chlorogenic acid, rosmarinic acid](image-url)
HCAs are absorbed easily from the stomach and intestine depending on their structure and compared to other complex phenolic compounds [76]. Ferulic acid and \( p \)-coumaric acid are also absorbed from intestine, jejunum, ileum and colon of rats [74]. However, chlorogenic acid, ester of caffeic and quinic acid, first hydrolysed and free caffeic acid is absorbed from the intestine [76]. In Caco-2 cell monayers, caffeic acid demonstrated that monocarboxylic acid transporters (MCTs), a transport system present across the intestinal epithelial cells, may be involved in the absorption process [77, 78]. \( p \)-Coumaric acid and ferulic acid also followed the same monocarboxylic acid transporter (MCT) system to cross the intestinal epithelium [77, 78]. However, passive diffusion mechanism is also important and not ignored for the absorption of ferulic acid in the stomach and Caco-2 cells [75, 79]. In addition, involvement of a \( \text{Na}^+ \)-dependent, carrier-mediated transport process are also involved in the uptake of cinnamic acid and ferulic acid across the brush border membrane of rat jejunum [80]. Bioavailability of cinnamic acid derivatives are reviewed recently [74, 76]. Various cinnamic acid derivatives can be found in plasma immediately after the oral administration and may show various health benefit in different diseases (Fig. 2).

**Effect of Hydroxycinnamic acid derivatives on various parameters of Metabolic syndrome**

**Effect of hydroxycinnamic acid derivatives in Inflammation**

Hydroxycinnamic acid derivatives showed anti-inflammatory properties both in vitro and in vivo [81]. Ferulic acid prevented the production of TNF-alpha and decreased Macrophage inflammatory protein-2 (MIP-2) levels in lipopolysaccharide (LPS)-stimulated RAW264.7 cells [82]. The transcription factor nuclear factor kappa B (NF-κB) plays a critical role in stress, immune, and inflammatory responses. Ferulic acid in cereals inhibits NF-κB activation [83]. Salt of ferulic acid, ferulate, exhibited antioxidant action by maintaining redox regulation, suppressing NF-κB activation and modulating the expression of NF-κB-induced, proinflammatory COX-2, iNOS, VCAM-1 and ICAM-1 in aged Sprague–Dawley rats [84]. NF-κB suppression by ferulate is mediated via suppressing the activation of NIK/IKK and MAPKs [84].

\( p \)-Coumaric acid prevented the increased cell-mediated immune responses and macrophage phagocytic index in rats [85]. \( p \)-Coumaric acid also decrease in the expression of inflammatory mediator TNF-α and circulating immune complexes in adjuvant induced arthritic rats [85]. \( p \)-Coumaric acid also inhibited the TNF-α-induced changes in levels of monocyte chemoattractant protein-1 (MCP-1), plasminogen activator inhibitor-1 (PAI-1), and intracellular reactive oxygen species (ROS) in 3 T3-L1 adipocytes [86]. Furthermore, \( p \)-coumaric acid increased the secretion and concentration of adiponectin, superoxide dismutase (SOD), glutathione (GSH), glutathione peroxidase (GPx), and glutathione S-transferase (GST) in TNF-α-treated 3 T3-L1 adipocytes [86].

Caffeic acid phenethyl ester (CAPE) non-selectively inhibited the activities of baculovirus-expressed hCOX-1 and hCOX-2 enzymes and inhibits prostaglandin synthesis and COX 2 in the rat carrageenan air pouch model of inflammation [87]. Caffeic acid and some of its derivatives such as caffeic acid phenethyl ester (CAPE) and octyl caffeate showed anti-inflammatory activity both in vitro and in vivo [88]. Caffeic acid derivatives suppressed the iNOS expression and prevented the production of NO from RAW macrophage cells. Moreover, butyl, octyl and CAPE derivatives of caffeic acid inhibited carrageenan-induced paw edema and prevented the increase in IL-1β levels in the mouse.
Caffeic acid supplementation reduced the inflammatory cytokines interleukin (IL)-beta, IL-6, tumor necrosis factor (TNF)-alpha and monocyte chemoattractant protein (MCP)-1 concentration in diabetic mice [16].

Chlorogenic acid, the ester of caffeic acid with quinic acid blocked UVB- or TPA-induced transactivation of AP-1 and NF-κB in JB6 P+ cells [89]. CGA inhibited lipopolysaccharide (LPS)-induced inflammatory response in RAW 264.7 cells mediated by decreasing cyclooxygenase (COX-2) at protein and mRNA levels and decreased the secretion of prostaglandin E2 (PGE2) [90].

### Table 1 Lipid lowering effect of hydroxycinnamic acid derivatives

| Derivatives          | Model                                                                 | Experimental outcome                                                                 | Reference |
|----------------------|-----------------------------------------------------------------------|-------------------------------------------------------------------------------------|-----------|
| Cinnamic acid        | High Cholesterol fed rats (Cinnamic acid (0.02 %, w/w))               | - Inhibited hepatic HMG-CoA reductase and ACAT activity.                             | [96]      |
|                      |                                                                       | - Reduced the elevated AST and AST concentration in plasma.                         |           |
|                      |                                                                       | - Lowered plasma and liver triglycerides and cholesterol concentrations.             |           |
|                      |                                                                       | - Improved antioxidant enzymes activities in erythrocytes and liver.                |           |
|                      | Cinnamic acid (30 mg/kg/day) for 7 weeks HFD diet fed Male Wistar rats | - The administration of CA to HFD-fed rats reduced the body weight gain              | [122]     |
|                      |                                                                       | - Reduced serum lipid profile and                                                  |           |
|                      |                                                                       | - Reverted back near to normal of lipase and ACE enzymes activities                |           |
| Ferulic acid         | C57BL/6 mice fed with high fat diet.                                  | - Lowered liver and plasma cholesterol by reducing fatty acid synthase and glucose 6 phosphate dehydrogenase | [97]      |
| Golden Syrian hamsters (choi-based hypercholesterolemic diet (HCD) containing 10 % coconut oil and 0.1 % cholesterol for 2 weeks) | - Lowered plasma lipid and lipoprotein cholesterol concentrations.                   | [98]      |
|                      |                                                                       | - Preserved the antioxidant status by preserving higher amount of Vitamin E in plasma. |           |
| Stroke-prone spontaneously hypertensive rats (SHRSP) | - Plasma total cholesterol and triglyceride levels were lower after 2 h administration. | [99]      |
|                      |                                                                       | - The mRNA expression of genes involved in lipid and drug metabolism was downregulated |           |
| Apolipoprotein E-deficient (apo E−/−) mice fed Western | - Lowered the Concentrations of total cholesterol (total-C), apolipoprotein B (apo B) in the plasma and epididymal adipose tissue wet weight | [101]     |
|                      |                                                                       | - Lowered hepatic ACAT and HMG-CoA reductase were only significantly.                |           |
| Male apo E−/− mice   | - Lowered The hepatic and erythrocyte thiobarbituric acid-reactive substances levels. | [100]     |
|                      |                                                                       | - Lowered the plasma total cholesterol concentration accompanied with a decreased hepatic acyl-coenzyme A: cholesterol acyltransferase activity. |           |
| Streptozotocin induced diabetes rat | - Reduced the elevated plasma lipid and blood glucose levels | [102]     |
| Caffeic acid         | High fat diet in mice (30 mg/kg of CAPE)                              | - Reduced plasma cholesterol and triglycerides.                                    | [117]     |
|                      |                                                                       | - Amelioration in hepatic steatosis.                                                |           |
|                      |                                                                       | - Increase in glucose sensitivity by improving phosphorylation of the insulin receptor substrate-2 and Akt phosphorylation. |           |
|                      |                                                                       | - Reduced the induction of the inflammatory pathway, c-jun-N terminal kinase, the nuclear factor kappa B, and cyclooxygenase-2 expression. |           |
| Chlorogenic acid     | ICR mice fed with high fat diet.                                       | - Lowered plasma cholesterol by reducing the activity of fatty acid synthase and HMG-CoA reductase and increased the fatty acid beta oxidation. | [15]      |
| Fa/fa Zucker Rats    | - Lowered plasma fasting cholesterol and triglycerides.                | [103]     |
| Streptozotocin (STZ)–nicotinamide (NA)-induced type 2 diabetic rats. (CGA 5 mg/kg) | - Lowered the plasma lipid; cholesterol, free fatty acids and triglycerides.        | [104]     |
|                      |                                                                       | - Lowered HMG-CoA reductase activity in liver and increased LPL activity in plasma.  |           |
| Derivatives | Model | Experimental outcome | Reference |
|------------|-------|----------------------|-----------|
| Cinnamic acid | 3 T3-L1 adipocytes | - Stimulated the secretion of adiponectin and the phosphorylation of AMPK in 3 T3-L1 adipocytes and therefore improves insulin sensitivity | [123] |
| | - Cinnamic acid (30 mg/kg/day) for 7 weeks | - The administration of CA to HFD-fed rats reduced the body weight gain. | [122] |
| | - HFD diet fed Male Wistar rats | | |
| Coumaric acid | 3 T3-L1 adipocytes | - Inhibition of adipogenesis in 3 T3-L1 adipocytes. | [124] |
| | - o-coumaric acid inhibited GPDH activity and the expression of PPARγ, C/EBPα and leptin and then up-regulated expression of adiponectin. | | |
| | 3 T3-L1 adipocytes | - p-Coumaric acid inhibited TNF-α-induced changes in levels of monocyte chemoattractant protein-1 (MCP-1), plasminogen activator inhibitor-1 (PAI-1), and intracellular reactive oxygen species (ROS) in 3 T3-L1 adipocytes. | [125] |
| | - p-Coumaric acid increased the secretion of adiponectin, superoxide dismutase (SOD), glutathione (GSH), glutathione peroxidase (GPx), and glutathione 5-transferase (GST) in TNF-α-treated 3 T3-L1 adipocytes | | |
| | Wistar rats fed a high fat diet (100 mg/kg) | - Decreased body weight, liver organ, and adipose tissue weights of peritoneal and epididymal fat pads. | [12] |
| | - Decreased hepatic triacylglycerol and cholesterol levels. | | |
| | - Enhanced the levels of glutathione (GSH), GSH peroxidase (GPx), GSH reductase (GRd), and GSH S-transferase (GST) in the hepatic tissue | | |
| Ferulic acid | high fat diet-induced obesity in mice | - Oryzanol or ferulic acid significantly suppressed the weight gain of the high fat diet-induced obesity in mice. | [97] |
| | - Ferulic acid is more effectively suppressed the weight gain compared to oryzanol. | | |
| Caffeic acid | 3 T3-L1 adipocytes | - Inhibitory effects on increased glycerol-3-phosphate dehydrogenase (GPDH) activity and an increased insulin receptor substrate 1 (IRS-1). | [126] |
| | - Reduced the levels of leptin, resistin, and tumor necrosis factor (TNF)-alpha. | | |
| | High-fat diet induced obese mice (0.02 % CFA of diet (wt/wt) dose) | - Lowered body weight, visceral fat mass and plasma leptin and insulin levels. | [15] |
| | - Inhibited fatty acid synthase, 3-hydroxy-3-methylglutaryl CoA reductase and acyl-CoA:cholesterol acyltransferase activities. | | |
| | - increased fatty acid β-oxidation activity and peroxisome proliferator-activated receptors α expression in the liver | | |
| Chlorogenic acid | High-fat diet induced obese mice (0.02 % CGA of diet (wt/wt) dose) | - Lowered body weight, visceral fat mass and plasma leptin and insulin levels. | [15] |
| | - Inhibited fatty acidsynthase, 3-hydroxy-3-methylglutaryl CoA reductase and acyl-CoA:cholesterol acyltransferase activities. | | |
| | - Increased fatty acid β-oxidation activity and peroxisome proliferator-activated receptors α expression in the liver | | |
| Streptozotocin (STZ)–nicotinamide (NA)-induced type 2 diabetic rats CGA (5 mg/kg b.w.) | - Decreased plasma and tissue triglycerides, free fatty acids. | [104] |
| | - Decreased the activity of HMG-CoA reductase. | | |
| | - Prevents lipid accumulation in liver. | | |
| Insulin resistant (fa/fa) Zucker rats (infused CGA 5 mg/Kg body weight/day) | - Fasting plasma cholesterol and triacylglycerols concentrations were significantly decreased. | [103] |
| Golden hamsters (80 mg CGA/kg body weight daily given peritonially) | - Lowered fasting serum triglyceride (TG), free fatty acid (FFA), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), glucose (FGS), and insulin (FSI). | [127] |
Chlorogenic acid also inhibited LPS induced inflammation of liver in mice and prevented the mRNA expression of toll-like receptor 4 (TLR4), TNF-α and NF-κB p65 subunit [91].

**Effect of hydroxycinnamic acid derivatives on lipid and fat metabolism**

Elevated plasma concentrations of total cholesterol (TC) and low density lipoprotein (LDL) cholesterol (and/or reduced high-density lipoprotein [HDL]) are commonly seen in dyslipidemia and strongly associated with cardiovascular disease, peripheral vascular disease and stroke [92]. High fat diet feeding in laboratory animals showed dyslipidemic condition similar to human dyslipidemia. Several plant based compounds e.g., plant stanols and sterols, tea-based catechins and theaflavins showed improvement in lowering plasma lipid profiles; however the clinical efficacy of many of these substances are not well studied [93]. Most of the hydroxycinnamic acid derivatives are effective against fat deposition and lowered plasma lipid profile and increases fat metabolism in liver (Table 1). Polyphenol rich red wine improved plasma lipid profiles by increasing HDL cholesterol levels, improve LDL oxidation [94] and improved the antioxidant status by reducing the oxidative stress in patients [95].

Cinnamic acid derivative supplementation lowered the plasma and liver triglycerides and cholesterol concentrations in high cholesterol fed rats [96]. Ferulic acid supplementation also lowered plasma lipid and cholesterol concentrations in various model of dyslipidemia such as C57BL/6 mice fed with high fat diet [97], Golden syrian hamsters fed with chow-based hypercholesterolemic diet [98], stroke-prone spontaneously hypertensive rats [99], apolipoprotein E-deficient (apo E−/−) mice fed Western diet [100, 101] and in streptozotocin induced diabetes rats [102]. Chlorogenic acid infusion in diabetic Zucker rats lowered the fasting plasma cholesterol and triacylglycerol concentrations significantly [103]. Chlorogenic acid also lowered the plasma cholesterol in ICR mice fed with high fat diet [15] and lipid, free fatty acids and triglycerides in Streptozotocin (STZ)–nicotinamide (NA)-induced type 2 diabetic rats [104].

Cholesterol lowering effect is attributed to the inhibition of the cholesterol synthesis and utilization of the free fatty acids in liver. HMG-CoA reductase is the rate regulating enzymes found in liver which is responsible for the cholesterol biosynthesis. Several statins selectively inhibited the HMG-CoA reductase in liver and lowered plasma cholesterol in hyperlipidemic patients [105, 106]. Hepatic ACAT is other type of enzymes that increased the utilization of fatty acid for cholesterol biosynthesis. Cinnamic acid derivatives such as cinnamic acid, ferulic acid, chlorogenic acid reduced the HMG-CoA reductase and ACAT activity in experimental animals [96, 101, 15, 104]. Ferulic acid decreased hepatic acyl-coenzyme A: cholesterol acyltransferase activity [100, 101] and down regulates the genes involved in lipid metabolism [99]. Moreover, Chlorogenic acid increased beta-oxidation and lypolitic lipase activity in diabetic animal [15, 104].

**Table 2** Effect of hydroxycinnamic acid derivatives on obesity and adipocyte dysfunction (Continued)

| High Cholesterol diet fed Sprague–Dawley rats (1 or 10 mg/kg/day p.o. CGA) | - Increased hepatic lipase (HL), lower contents of TG and FFA in liver and lower activity of lipoprotein lipase (LPL) in skeletal muscle. | - Lowered total cholesterol, triglycerides, high-density lipoprotein and low-density lipoprotein. | - Up-regulated of peroxisome proliferation-activated receptor α mRNA in liver. |
|---|---|---|---|

Effect of hydroxycinnamic acid derivatives on body weight and obesity

Hydroxycinnamic acids are also effective against body weight gain, fat deposition and dysfunction of the adipocytes due to high fat diet feeding in animal model (Table 2). Adipocyte proliferation and differentiation plays critical role on adipose tissue deposition and dysfunction. 3 T3-L1 preadipocytes are excellent cell lines for studying the anti-obesity effect of various therapeutic agents. Addition of phenolic acids to the growth medium decreased the cell population of 3 T3-L1 preadipocytes in vitro [107]. Chlorogenic acid, o-coumaric acid, and m-coumaric acid caused cell cycle arrest in the G1 phase in 3 T3-L1 preadipocytes [107]. Ferulic acid prevented the body weight gain in high fat diet fed mice and decreased the plasma and liver lipids, triglycerides and total cholesterol [97]. Ferulic acid also decreased the activity of hepatic lipogenic enzymes, such as G6PD, ME, and FAS which are responsible for the cholesterol and fatty acid synthesis [97]. Chlorogenic acid showed anti-obesity effect on mice fed with a high fat diet [15]. Chlorogenic acid also lowered the visceral fat mass and plasma leptin and insulin levels compared to the high-fat control group [15]. Caffeic acid and chlorogenic acid significantly inhibited fatty acid synthase, 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA) and peroxisome proliferator-activated receptor α (PPAR-α) activity [108]. Chlorogenic acid also inhibited LPS induced inflammation of liver in mice and prevented the mRNA expression of toll-like receptor 4 (TLR4), TNF-α and NF-κB p65 subunit [91].
| Derivatives       | Model                                                   | Experimental outcome                                                                                                                                                                                                 | Reference |
|------------------|---------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Cinnamic acid    | TNF-α-treated insulin-resistant mouse FL83B hepatocytes. | - Increased expression of glycogen synthase, whereas the expression of glycogen synthase kinase and phosphorylation of glycogen synthase at Ser641 in insulin-resistant mouse hepatocytes was decreased.                                      | [111]     |
|                  | STZ-induced diabetic Wistar Albino rats                 | - Improved glucose tolerance and carbohydrate metabolizing enzymes,                                                                                                                                                  | [13]      |
| Ferulic acid     | STZ-induced diabetic mice (0.01 and 0.1 % FA of diet)    | - Decreased elevated blood glucose level                                                                                                                                                                             | [14]      |
|                  | KK-A' mice (0.05 % FA of Diet)                          | - Suppress blood glucose level                                                                                                                                                                                        | [14]      |
|                  | C57BL/KsJ db/db mice                                    | - Decreased blood glucose level by increasing glycogen synthesis. Increased glucokinase activity.                                                                                                                     | [112]     |
| Streptozotocin   | induced diabetes rats                                    | - Prevents lipid peroxidation and improved the antioxidant enzymes such as glutathione peroxidase (GPx), superoxide dismutase (SOD) and catalase (CAT)                                                                 | [114]     |
| Otsuka Long-Evans| Fatty (OLETF) diabetic rats (0.2 % FA in diet)          | - Improved                                                                                                                                                                                                          |           |
| Male C57BL/6 N   | mice (0.5 % FA of diet)                                 | - Lower blood glucose level and glucose-6-phosphatase (G6pase) and phosphoenolpyruvate carboxykinase (PEPCK) activities.                                                                                             | [113]     |
| Stroke-prone     | spontaneously hypertensive rats (SHRsp) (0-01 g/kg FA of| - Improved hypertension as well as glucose tolerance, plasma nitric oxide (NOx). Also increased several mRNA expressions of metabolic parameters involved in glucose and lipid metabolisms                                      | [129]     |
|                  | diet)                                                   | - FA treatment to diabetic animals restored blood glucose, serum insulin, glucose tolerance, and insulin tolerance to normal range.                                                                                 | [130]     |
|                  | high-fat and fructose-induced type 2 diabetic adult male | - Hepatic glycogen concentration, activity of glycogen synthase, and glucokinase were significantly increased, whereas activity of glycogen phosphorylase and enzymes of gluconeogenesis (phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase)) were decreased in diabetic animals due to FA treatment |           |
|                  | rats                                                   | - Authors suggested that FA treatment reduced the GLUT2 expression in diabetic animals by impairing the interaction between these transcription factors (SREBP1c, HNF1a and HNF3β) and GLUT2 gene promoter.                                      | [131]     |
|                  | FA (50 mg/kg body weight · day (−1), orally) for 30  | - Reduction of the blood glucose and glycosylated hemoglobin levels. Caffeic acid also markedly increased glucokinase activity and its mRNA expression and glycogen content and simultaneously lowered glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities and their respective mRNA expressions, accompanied by a reduction in the glucose transporter 2 expression in the liver | [115]     |
| Caffeic acid     | C57BL/KsL- db/db mice                                   | - Improved lipid peroxidation and antioxidant enzyme status in liver of rats                                                                                                                                            | [132]     |
| Streptozotocin   | induced diabetes rats                                    | - Tumor necrosis factor-α was used to induce insulin resistance. may promote insulin receptor tyrosyl phosphorylation, up-regulate the expression of insulin signal associated proteins, including insulin receptor, phosphatidylinositol-3 kinase, glycogen synthase, and glucose transporter-2, increase the uptake of glucose, and alleviate insulin resistance | [118]     |
| Mouse liver      | FL83B cells                                             | - Increased expression of glycogen synthase, whereas the expression of glycogen synthase kinase and phosphorylation of glycogen synthase at Ser641 in insulin-resistant mouse hepatocytes was decreased.                               | [111]     |
|                  | TNF-α-treated insulin-resistant mouse FL83B hepatocytes.| - Also suppressed the expression of hepatic nuclear factor-4 and activity of phosphoenolpyruvate carboxykinase                                                                                                      |           |
| High fat diet    | in male BLTW: CD1 (ICR) mice                            | - Improved the glucose intolerance and normalized plasma insulin, adiponectin. also suppress TNF-alpha, PEPCK and increased GLUT4                                                                                   | [119]     |
| L6-GLUT4myc      | cells                                                  | - Increased glucose uptake and GLUT4 translocation to the cell membrane of L6-GLUT4myc cells.                                                                                                                         | [120]     |
reductase and acyl-CoA:cholesterol acyltransferase activities, while they increased fatty acid β-oxidation activity and peroxisome proliferator-activated receptors α expression in the liver compared to the high-fat group [15].

**Table 3 Effect of hydroxycinnamic acid derivatives on diabetes (Continued)**

| Condition | Effect                                                                 |
|-----------|------------------------------------------------------------------------|
| Streptozocin (STZ)-induced diabetic rats | Increased phosphorylation of AMPK and increased GLUT4 content. | [116] |
|            | Phosphoenolpyruvate carboxykinase mRNA expression was decreased. | |
|            | Decreased the fasting blood levels of glucose, alanine aminotransferase, cholesterol, and triglyceride induced by diabetes. | |
|            | Increased expressions of glucokinase and pyruvate kinase mRNAs and increased the liver glycogen level. | |
| Swiss mice fed high fat diet | Improved glucose intolerance in high fat diet fed mice. | [117] |
|            | Improvement in insulin-stimulated phosphorylation of the insulin receptor substrate-2, followed by an increase in Akt phosphorylation. | |
|            | Reduced the induction of the inflammatory pathway, c-jun-N-terminal kinase, the nuclear factor kappa B, and cyclooxygenase-2 expression. | |
| Male Sprague-Dawley rats | Increased the phosphorylation of AMPKα Thr172 in skeletal muscle. | [113] |
|            | AMPKα2 activity increased significantly, whereas AMPKα1 activity did not change. | |
| Male Balb/cA mice (2.5 % CFA of Diet) | Increased plasma insulin and decreased blood glucose and plasma HbA1c levels. | [11] |
|            | Lowered renal levels of IL-6, IL-1b, tumor necrosis factor (TNF)-α and monocyte chemoattractant protein 1 (MCP-1) and decreased TNF alpha and MCP-1 mRNA expression. | |
| Chlorogenic acid db/db mice | Improved the fasting blood glucose level. | [112] |
|            | Stimulates glucose transport in skeletal muscle via the GLUT4 translocation and phosphorylation of AMPK and Akt. | |
| Male Sprague-Dawley rats (CGA (120 mg · kg⁻¹) | Improved glucose metabolism as seen in decreased AUC. | [134] |

**Effect of hydroxycinnamic acid derivatives on diabetes and insulin resistance**

Hyperglycemia and insulin resistance are commonly seen in obesity [108–110]. Polyphenolic compounds showed prevention of metabolic disorder associated with hyperglycemia and diabetes. The mechanisms behind these benefits have multiple targets. Some molecules prevented the beta cell destruction in pancreas thereby increasing the insulin secretion. Others include inhibition of carbohydrate digestive enzymes, increased glycogen synthesis, increased glucose uptake in muscle tissues and adipocytes by phosphorylation of AMPK and increased GLUT4 content as well as increasing glucose metabolism. Hydroxycinnamic acid derivatives also showed considerable hypoglycaemic activities in experimental condition (Table 3). Cinnamic acid improved glucose intolerance and insulin resistance in STZ-induced diabetic rats [13]. Cinnamic acid also increased the expression of glycogen synthase, whereas the expression of glycogen synthase kinase and phosphorylation of glycogen synthase at Ser641 in TNF-α-treated insulin-resistant mouse hepatocytes was decreased [111]. Rice bran fraction and ferulic acid reduced the blood glucose concentrations and increased the insulin in plasma of diabetic C57BL/KsJ db/db mice [112]. Glucose lowering effect by ferulic acid was also seen in KK-AY mice [14] and STZ induced diabetic mice [14]. Ferulic acid also increased glucokinase activity [112] and decreased glucose-6-phosphatase (G6pase) and phosphoenolpyruvate carboxykinase (PEPCK) activities in liver [113]. Moreover, ferulic acid prevented lipid peroxidation and improved the antioxidant enzymes such as glutathione peroxidase (GPx), superoxide dismutase (SOD) and catalase (CAT) [114].

Caffeic acid has been studied extensively in experimental diabetes and related complications. Caffeic acid lowered blood glucose level in C57BL/KsJ-db/db mice [115] and Streptozotocin (STZ)-induced diabetic rats [116]. Caffeic acid also improved insulin level in plasma of male Balb/cA mice [11] and improved glucose intolerance in high fat diet fed male mice [117]. Caffeic acid improved insulin resistance by promoting insulin receptor tyrosyl phosphorylation, up-regulate the expression of insulin signal associated proteins, including insulin receptor, phosphatidylinositol-3 kinase, glycogen synthase, and glucose transporter-2, increase the uptake of glucose in tumor necrosis factor-α induced insulin resistant mouse liver FL83B cells [118]. Other studies showed that caffeic acid decreased the inflammatory cytokines [119] and reduced the induction of the inflammatory pathway, c-jun-N-terminal kinase, the nuclear
factor kappa B, and cyclooxygenase-2 expression [11]. Furthermore, Caffeic acid increased increased phosphorylation of AMPKs and increased glucose uptake and GLUT4 content in L6-GLUT4myc cells [120]. Chlorogenic acid also follows the similar mechanism for improving insulin resistance and diabetes. Chlorogenic acid stimulates glucose transport in skeletal muscle via the GLUT 4 translocation and phosphorylation of AMPK and Akt in db/db mice [121].

Conclusion
Recent research has provided the scientific benefit of these phenolic acids and confirmed the important role of phenolic acids in the prevention and treatment of obesity, diabetes and associated disorders. Phenolic acids could favourably affect most of the leading aspects of obesity including diabetes, including insulin resistance, hyperglycemia, hyperlipidemia, and adipocyte dysfunction and inflammation (Fig. 3). Despite the potential benefits of these natural products in preclinical studies, scanty literatures have been found on any beneficial effect from clinical trials of phenolic acids so far. Studies are thus required in humans to confirm the potential benefit of phenolic acids in limiting obesity and other associated disorders. Furthermore, multiple approaches are also needed to overcome limited solubility and poor bioavailability of phenolic acids. These include synthesis of phenolic acids derivatives and development of novel drug delivery system and formulations such as nanoparticles, liposomal encapsulation, emulsions, and sustained released tablets. Therefore, enhanced bioavailability and convinced clinical trial results of phenolic acids could bring these promising natural products to the forefront of therapeutic agents for obesity.

Abbreviations
AGES: advanced glycation end products; AMPK: AMP-activated protein kinase; AP-1: activator protein-1; DNA binding; CPT-1: carnitine palmitoyl transferase-1; EGCG: epigalocatechin gallate; ERK: extracellular signal-regulated protein kinase; GIP: glucose-dependent insulinotropic polypeptide; GLUT: glucose transporter; MAPK: mitogen-activated protein kinases; MMP-2: matrix metalloproteinase-2; NF-κB: nuclear factor kappa-B; Nrf2: nuclear factor erythroid 2 related factor 2; PEPCK: glucose-6-phosphatase and phosphoenolpyruvate carboxykinase; PG12: increased prostacyclin I2; PI3: phosphoinositide 3 kinase/protein kinase B; PPARα: peroxisome proliferator-activated receptor alpha; ROS: reactive oxygen species; SGLT: sodium-dependent glucose transporter; TGF-β: transforming growth factor-β; TXA2: thromboxane A2; UCP2: uncoupling protein 2; VEGF: vascular endothelial growth factor.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
All authors read and approved the final manuscript.

Author details
1Department of Pharmaceutical Sciences, North South University Bangladesh, Dhaka, Bangladesh. 2School of Biomedical Sciences, Charles Sturt University,
Wagga Wagga, New South Wales, Australia. *BCSIR Laboratories, Bangladesh Council of Scientific and Industrial Research (BCSIR), Dhaka, Bangladesh.

Received: 20 September 2015 Accepted: 2 March 2016
Published online: 11 April 2016

References

1. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011;34(6):1249–57.
2. Gupta N, Goel K, Shah P, Misra A. Childhood obesity in developing countries: epidemiology, determinants, and prevention. Endocr Rev. 2012;33(1):48–70.
3. Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev. 2012;70(1):13–21.
4. Bruno G, Landi A. Epidemiology and costs of diabetes. Transplant Proc. 2011;43(1):327–9.
5. Marinou K, Tousoulis D, Antonopoulos AS, Stefanadis C. Obesity and cardiovascular disease: from pathophysiology to risk stratification. Int J Cardiol. 2010;138(1):3–8.
6. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, Macnnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB et al. Body-mass index and mortality among 1.46 million white adults. New Engl J Med. 2010;363(23):2211–9.
7. Lazarou C, Panagiotakos D, Matalas AL. The role of diet in prevention and management of type 2 diabetes: implications for public health. Crit Rev Food Sci Nutr. 2012;52(5):382–9.
8. Pistillo F, Battino M. Role of plant-based diets in the prevention and regression of metabolic syndrome and neurodegenerative diseases. Trends Food Sci Technol. 2014.
9. Rajarathnam S, Shashirakha MN, Mallikarjuna SE. Status of bioactive compounds in foods, with focus on fruits and vegetables. Crit Rev Food Sci Nutr. 2013;53(5):1234–39. doi:10.1080/10408398.2012.692736.
10. Pistillo F, Battino M. Role of plant-based diets in the prevention and regression of metabolic syndrome and neurodegenerative diseases. Trends Food Sci Technol. 2014.
11. Kasetti RB, Nabi SA, Swapna S, Apparao C. Cinnamic acid as one of the bioactive compounds that could be responsible for the anti-inflammatory and anti-obesity properties. Biochem Biophys Res Commun. 2014;449(1):265–71.
12. Gagné G, Iyengar R, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes. J Biol Chem. 2010;285(8):5748–57.
13. Hey-Mogensen M, Jeppesen J, Madsen K, Kiens B, Franch J. Obesity augments the age-induced increase in mitochondrial capacity for H2O2 release in Zucker fatty rats. Acta Physiol. 2012;204(3):354–61.
14. James AM, Collins Y, Logan A, Murphy MP. Mitochondrial oxidative stress and the metabolic syndrome. Trends Endocrinol Metab. 2012;23(9):429–34.
15. Puiipserve P, Spiegelman BM. Peroxisome proliferator-activated receptor-y coactivator 1a (PGC-1α): transcriptional coactivator and metabolic regulator. Endocr Rev. 2003;24(1):78–90.
16. Vega RB, Huss JM, Kelly DF. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol. 2000;20(5):1868–76.
17. Hock MB, Naulli A. Transcriptional control of mitochondrial biogenesis and function. Annu Rev Physiol. 2009;71:177–203.
18. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 2009(95):407–16.
19. Cantó C, Auwerx J. PGC-1[alpha], SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol. 2009;20(2):98–105. doi:10.1097/MOL.0b013e3282848d2a523824.
20. Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes. 2008;32(5):57–12.
21. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1(1):15–25.
22. Zong H, Ren JM, Young LH, Pypaert M, Ju M, Bimbbaum MJ, Shulman GI. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy depriviation. Proc Natl Acad Sci. 2002;99(25):15983–7.
23. Garcia-Roves PM, Olser ME, Holstrom MH, Zierath JR. Gain-of-function R225Q mutation in AMP-activated protein kinase y3 subunit increases mitochondrial biogenesis in glycolytic skeletal muscle. J Biol Chem. 2008;283(5):324–34.
24. Long Y, Bames B, Mahlapuu M, Steiler T, Martinsson S, Leng Y, Wallberg-Henriksson H, Andersson L, Zierath J. Role of AMP-activated protein kinase in the coordinated expression of genes controlling glucose and lipid metabolism in mouse white skeletal muscle. Diabetologia. 2005;48(1):2354–64.
25. Fryer LGD, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 2002;277(20):19226–33.
26. Brunnmar B, Ståkel K, Gras F, Scharf N, Alltham A, Cla R, Roden M, Gnaiger E, Nohl H, Waldhauel W et al. Thiazolinediones, like metformin, inhibit respiratory complex I of diabetes. Diabetologia. 2004;47(4):1052–9.
27. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, Dickinson R, Adler A, Gagne G, Iyengar R et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006;6(6):403–16.
28. Suwa M, Nakano H, Kumagai S. Effects of chronic aICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles. J Appl Physiol. 2003;95(3):960–8.
29. Lee CJ, Kim M, Park H-S, Kim HS, Jeon MJ, Oh KS, Koh EH, Won JC, Kim MS, Oh GT, et al. AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARβ and PGC-1. Biochem Biophys Res Commun. 2006;346(1):291–5.
30. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor-y coactivator 1a (PGC-1α): adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology. 1994;135(2):798–800.
31. Tontonoz P, Hu E, Graves RA, Budavari A, Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8(10):1294–34.
32. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Frucht DJ, Deeb S et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem. 1997;272(30):18779–80.
46. Cock TA, Houten SM, Auwerx J. Peroxosome proliferator-activated receptor- [gamma]: too much of a good thing causes harm. EMBO Rep. 2004;5(2): 142–7.

47. Miles PD, Barak Y, He W, Evans RM, Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest. 2000;105(3): 287–92.

48. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Kameda K, Sato S, Nakano R, Ishii C, Sugiyama T, et al. PPAR-γ mediates high-fat diet induced adipocyte hypertrophy and insulin resistance. Mol Cell. 1999;4(4):597–609.

49. Sztanto A, Nagy L. The many faces of PPARgamma: anti-inflammatory by any means? Immunobiology. 2008;213(9):789–803.

50. Leflher M, Lazar MA. The many faces of PPARgamma. Cell. 2005;123(6):993–9.

51. He W, Barak Y, Hefener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM, Evans RM. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A. 2003;100(26):15712–7.

52. Hefener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Willie J, Evans RM, Olefsky J. Muscle-specific Pparg deletion causes insulin resistance. Nat Med. 2003;9(12):1491–7.

53. Norris AW, Chen L, Fisher SJ, Sianto J, Ristow M, Jojic AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, et al. Muscle-specific PPAR-gamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest. 2003;112(4):668–88.

54. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Breuer B Jr, Reitman ML, Gonzalez FJ. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest. 2003;111(5):737–47.

55. Rangwala SM, Rhoades B, Shapiro JS, Rich AS, Kim JK, Shulman GL, Kaestner KH, Lazar MA. Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev Cell. 2003;5(4):657–63.

56. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WD, William TM, Klever SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARY). J Biol Chem. 1995;270(22):12953–6.

57. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med. 2003;115(8):42–8.

58. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 1999;92(6):829–39.

59. Liang H, Ward WF. PGC-1a: a key regulator of energy metabolism. Adv Physiol Educ. 2006;30(4):45–51.

60. Fernandez-Marcos PJ, Auwerx J. Regulation of PGC-1α in insulin resistance. Cell. 2006;125(5):1300–8.

61. Kim EO, Min KJ, Kwon TK, Um BH, Moreau RA, Choi SW. Anti-inflammatory activity of hydroxycinnamic acid derivatives isolated from corn bran in lipopolysaccharide-stimulated Raw 264.7 macrophages. Food Chem Toxicol. 2012;50(5):1309–16.

62. Saiki S, Ochiai H, Nakajima K, Terawaka S. Inhibitory effect of ferulic acid on macrophage inflammatory protein-2 production in a murine macrophage cell line, Raw264.7. Cytokine. 1997;9(4):242–6.

63. Holes AS, Grimmer S, Jensen MR, Sahström S. Synergistic and suppressive effects of dietary phenolic acids and other phytochemicals from cereal extracts on nuclear factor kappa B activity. Food Chem. 2012;133(3):969–77.

64. Jung KJ, Go EK, Kim JY, Yu BP, Chung HY. Suppression of age-related renal changes in NF-κB and its target gene expression by dietary ferulate. J Nutr Biochem. 2009;20(5):378–88.

65. Pragasm S, Venketesan V, Rascol M. Immunomodulatory and anti-inflammatory effect of p-coumaric acid, a common dietary polyphenol on experimental inflammation in rats. Inflammation. 2012;1–8.

66. Yen GC, Chen YC, Chang WT, Hsu CL. Effects of Polyphenolic Compounds on Tumor Necrosis Factor-α (TNF-α)-Induced Changes of Adipokines and Oxidative Stress in 3 T3-L1 Adipocytes. J Agric Food Chem. 2010;58(2): 546–51.

67. Michaluart P, Masferrer JL, Carothers AM, Subbaramaiah K, Zweifel BS, Koboldt C, Mestre JR, Grunberger D, Sacks PG, Tanabe T, et al. Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. Cancer Res. 1999;59(10):2347–52.

68. da Cunha FM, Duma D, Assreyu J, Buzzi FC, Niero R, Campos MM, Caliato JB. Caffeic acid derivatives: in vitro and in vivo anti-inflammatory properties. Free Radic Res. 2006;40(5):411–25.

69. Feng R, Lu Y, Bowman LL, Qian Y, Castranova V, Ding M. Inhibition of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. Cancer Res. 1999;59(10):2347–52.

70. Shao J, Fu J, Zhao Z, Kong X, Huang H, Luo L, Yin Z. Cholecalciferol inhibits lipopolysaccharide-induced cyclooxygenase-2 expression in RAW264.7 cells through suppressing NF-κB and MAPKs activity. J Immunopharmacol. 2009;39(9):1042–8.

71. Xu Y, Chen J, Yu X, Tao W, Jiang F, Yin Z, Liu C. Protective effects of cholecalciferol on acute hepatotoxicity induced by lipopolysaccharide in mice. Inflammation Res. 2010;59(10):871–7.
92. Fodorwsian HR, Barnard ND. Effects of plant-based diets on plasma lipids. Am J Cardiol. 2009;104(7):947–56.

93. McGowan M, Prouk S. Nutritional supplements and serum lipids: Does anything work? Curr Atheroscler Rep. 2009;11(6):470–8.

94. Hansen AS, Markmann P, Dragsted LO, Finne Nielsen IL, Nielsen SE, Gronbaek M. Effect of red wine and red grape extract on blood lipids, haemostatic factors, and other risk factors for cardiovascular disease. Eur J Clin Nutr. 2005;59(9):449–55.

95. Pignatelli P, Ghiselli A, Buchetti B, Carnevale R, Natella F, Germano G, Fimognari F, Di Sonto L, Lentini L, Voli F. Polyphenols synergistically inhibit oxidative stress in subjects given red and white wine. Atherosclerosis. 2006;188(3):77–85.

96. Lee MK, Park YB, Moon SS, Bok SH, Kim DJ, Ha TY, Jeong TS, Jeong KS, Choi MS. Hypocholesterolemic and antioxidant properties of 3-(4-hydroxy)propanoic acid derivatives in high-cholesterol fed rats. Chem Biol Interact. 2007;170(1):19–27.

97. Jin Son M, Rico CW, Hyun Nam S, Young Kang M. Influence of ozyanol and ferulic Acid on the lipid metabolism and antioxidative status in high fat-fed mice. J Clin Biochem Nutr. 2010;46(2):150–5.

98. Wilson TA, Nicolosi RJ, Woolfrey F, Kritchkevsky D. Rice bran oil and ozyanol reduce plasma lipid and lipoprotein cholesterol concentrations and aortic cholesterol ester accumulation to a greater extent than ferulic acid in hypercholesterolemic hamsters. J Nutr Biochem. 2007;18(2):105–12.

99. Adriansyah, Ohsaki Y, Shirakawa H, Koseki T, Komai M. Novel effects of a single administration of ferulic acid on the regulation of blood pressure and the hepatic lipid metabolic profile in stroke-prone spontaneously hypertensive rats. J Agric Food Chem. 2008;56(8):2825–30.

100. Kwon EY, Cho YY, Do GM, Kim HJ, Jeon SM, Park YB, Lee MK, Min TS, Choi MS. Actions of ferulic acid and vitamin E on prevention of hypercholesterolemia and atherosclenic lesion formation in apolipoprotein E-deficient mice. J Med Food. 2009;12(5):996–1003.

101. Kwon EY, Do GM, Cho YY, Park YB, Jeon SM, Choi MS. Anti-atherosclerotic property of ferulic acid in apolipoprotein E-deficient mice fed Western diet. Comparison with clofibrate. Food Chem Toxicol. 2010;48(8–9):2298–303.

102. Sri Balasubashini M, Rukkumani R, Menon VP. Protective effects of ferulic acid on hyperlipidemic diabetic rats. Acta Diabetol. 2003;40(3):118–22.

103. de Sotillo DV, Hadley M. Chlorogenic acid modifies plasma and liver concentrations of cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats. J Nutr Biochem. 2002;13(12):717–26.

104. Karthikesan K, Pari L, Menon VP. Antihyperglycemic effect of chlorogenic acid and tetrahydrocinnamic acid in rats subjected to diabeticogenic agents. Chem Biol Interact. 2010;183(3):643–50.

105. Gazzero P, Proto MC, Gangemi G, Malaffitano AM, Ciaglia E, Pisanti S, Santoro A, Laeza C, Bifulco M. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Res. 2012;66(1):102–46.

106. Pahan K. Lipid-lowering drugs. Cell Mol Life Sci. 2006;63(10):1165–78.

107. Hsu CL, Yen GC. Effects of flavonoids and phenolic acids on the inhibition of adipogenesis in 3 T3-L1 adipocytes. J Agric Food Chem. 2007;55(2):8404–10.

108. Yen GC, Chen YC, Chang WT, Hu CL. Effects of polyphenolic compounds on tumor necrosis factor-alpha (TNF-alpha)-induced changes of adipokines and oxidative stress in 3 T3-L1 adipocytes. J Agric Food Chem. 2011;59(2):546–51.

109. Juman S, Yasui N, Okuda H, Ueda A, Negishi H, Miki T, Ikeda K. Caffeic acid phenethyl ester suppresses the production of adipocytokines, leptin, tumor necrosis factor-alpha and resistin, during differentiation to adipocytes in 3 T3-L1 cells. Biol Pharm Bull. 2011;34(4):490–4.

110. Li S-Y, Chang CQ, Ma FY, Yu CL. Modulating effects of chlorogenic acid on lipids and glucose metabolism and expression of hepatic peroxisome proliferator-activated receptor-α in golden hamsters Fed on high Fat diet. Biomed Environ Sci. 2009;22(2):122–9.

111. Wan CW, Wong CN, Pin WK, Wong MH, Kwock CY, Chan RY, Yu PH, Chan SW. Chlorogenic acid exhibits cholesterol lowering and fatty liver attenuating properties by Up-regulating the gene expression of PPAR-alpha in hypercholesterolemic rats induced with a high-cholesterol diet. Phytother Res. 2012;27(4):545–51.

112. Adriansyah, Shirakawa H, Komai M. Driselase-treated fraction of rice bran is a more effective dietary factor to improve hypertension, glucose and lipid metabolism in stroke-prone spontaneously hypertensive rats compared to ferulic acid. Br J Nutr. 2007;97(1):67–76.

113. Narasimhan A, Chinnaiyan M, Karunade B. Ferulic acid exerts its antiobesity effect by modulating insulin-signalling molecules in the liver of high-fat diet and fructose-induced type-2 diabetic adult male rat. Appl Physiol Nutr Metab. 2015.40(8):769–81.

114. Narasimhan A, Chinnaiyan M, Karunade B. Ferulic acid regulates hepatic GLUT2 gene expression in high fat and fructose-induced type-2 diabetic adult male rat. Eur J Pharmacol. 2015.761:391–7.

115. Yilmaz HR, Uz E, Yucel N, Altuntas I, Ozcelik N. Protective effect of caffeic acid phenethyl ester (CAPE) on lipid peroxidation and antioxidant enzymes in diabetic rat liver. J Biochem Mol Toxicol. 2004;18(4):234–8.

116. Tsuda S, Eqawa T, Ma X, Oshima R, Kurogi E, Hayashi T. Coffee polyphenol caffeic acid but not chlorogenic acid increases SAMP-activated protein kinase and insulin-independent glucose transport in rat skeletal muscle. J Nutr Biochem. 2012;23(11):1403–9.

117. Tunnicliffe JM, Eller LK, Reimer RA, Hittel DS, Shearer J. Chlorogenic acid differentially affects postprandial glucose and glucose-dependent insulinotropic polypeptide response in rats. Appl Physiol Nutr Metab. 2011;36(5):650–9.